Pfizer Statistics
Total Valuation
Pfizer has a market cap or net worth of $146.73 billion. The enterprise value is $204.83 billion.
| Market Cap | 146.73B |
| Enterprise Value | 204.83B |
Important Dates
The next confirmed earnings date is Wednesday, May 1, 2024, before market open.
| Earnings Date | May 1, 2024 |
| Ex-Dividend Date | Jan 25, 2024 |
Share Statistics
Pfizer has 5.65 billion shares outstanding. The number of shares has decreased by -0.42% in one year.
| Shares Outstanding | 5.65B |
| Shares Change (YoY) | -0.42% |
| Shares Change (QoQ) | +0.85% |
| Owned by Insiders (%) | 0.05% |
| Owned by Institutions (%) | 69.90% |
| Float | 5.64B |
Valuation Ratios
The trailing PE ratio is 69.74 and the forward PE ratio is 11.48. Pfizer's PEG ratio is 0.26.
| PE Ratio | 69.74 |
| Forward PE | 11.48 |
| PS Ratio | 2.49 |
| Forward PS | 2.41 |
| PB Ratio | 1.64 |
| P/FCF Ratio | 30.38 |
| PEG Ratio | 0.26 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 28.08, with an EV/FCF ratio of 42.73.
| EV / Earnings | 96.66 |
| EV / Sales | 3.50 |
| EV / EBITDA | 28.08 |
| EV / EBIT | 204.01 |
| EV / FCF | 42.73 |
Financial Position
The company has a current ratio of 0.91, with a Debt / Equity ratio of 0.81.
| Current Ratio | 0.91 |
| Quick Ratio | 0.50 |
| Debt / Equity | 0.81 |
| Debt / EBITDA | 9.86 |
| Debt / FCF | 15.00 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 2.20% and return on invested capital (ROIC) is 1.39%.
| Return on Equity (ROE) | 2.20% |
| Return on Assets (ROA) | 1.00% |
| Return on Capital (ROIC) | 1.39% |
| Revenue Per Employee | $664,727 |
| Profits Per Employee | $24,080 |
| Employee Count | 88,000 |
| Asset Turnover | 0.27 |
| Inventory Turnover | 2.60 |
Taxes
| Income Tax | -1.12B |
| Effective Tax Rate | -111.06% |
Stock Price Statistics
The stock price has decreased by -35.40% in the last 52 weeks. The beta is 0.57, so Pfizer's price volatility has been lower than the market average.
| Beta (1Y) | 0.57 |
| 52-Week Price Change | -35.40% |
| 50-Day Moving Average | 27.11 |
| 200-Day Moving Average | 30.74 |
| Relative Strength Index (RSI) | 39.73 |
| Average Volume (30 Days) | 42,898,575 |
Short Selling Information
The latest short interest is 65.00 million, so 1.15% of the outstanding shares have been sold short.
| Short Interest | 65.00M |
| Short Previous Month | 66.12M |
| Short % of Shares Out | 1.15% |
| Short % of Float | 1.15% |
| Short Ratio (days to cover) | 1.40 |
Income Statement
In the last 12 months, Pfizer had revenue of $58.50 billion and earned $2.12 billion in profits. Earnings per share was $0.37.
| Revenue | 58.50B |
| Gross Profit | 33.54B |
| Operating Income | 1.06B |
| Pretax Income | 1.00B |
| Net Income | 2.12B |
| EBITDA | 7.29B |
| EBIT | 1.00B |
| Earnings Per Share (EPS) | $0.37 |
Balance Sheet
The company has $12.69 billion in cash and $71.89 billion in debt, giving a net cash position of -$59.20 billion or -$10.48 per share.
| Cash & Cash Equivalents | 12.69B |
| Total Debt | 71.89B |
| Net Cash | -59.20B |
| Net Cash Per Share | -$10.48 |
| Equity / Book Value | 89.01B |
| Book Value Per Share | 15.76 |
| Working Capital | -4.46B |
Cash Flow
In the last 12 months, operating cash flow was $8.70 billion and capital expenditures -$3.91 billion, giving a free cash flow of $4.79 billion.
| Operating Cash Flow | 8.70B |
| Capital Expenditures | -3.91B |
| Free Cash Flow | 4.79B |
| FCF Per Share | $0.85 |
Margins
Gross margin is 57.34%, with operating and profit margins of 1.81% and 3.62%.
| Gross Margin | 57.34% |
| Operating Margin | 1.81% |
| Pretax Margin | 1.72% |
| Profit Margin | 3.62% |
| EBITDA Margin | 12.47% |
| EBIT Margin | 1.72% |
| FCF Margin | 8.19% |
Dividends & Yields
This stock pays an annual dividend of $1.68, which amounts to a dividend yield of 6.46%.
| Dividend Per Share | $1.68 |
| Dividend Yield | 6.46% |
| Dividend Growth (YoY) | 2.48% |
| Years of Dividend Growth | 13 |
| Payout Ratio | 454.05% |
| Buyback Yield | 0.42% |
| Shareholder Yield | 6.93% |
| Earnings Yield | 1.46% |
| FCF Yield | 3.29% |
Analyst Forecast
The average price target for Pfizer is $36.88, which is 41.87% higher than the current price. The consensus rating is "Buy".
| Price Target | $36.88 |
| Price Target Difference | 41.87% |
| Analyst Consensus | Buy |
| Analyst Count | 17 |
| Revenue Growth Forecast (5Y) | 2.28% |
| EPS Growth Forecast (5Y) | 58.51% |
Stock Splits
The last stock split was on November 17, 2020. It was a forward split with a ratio of 1054:1000.
| Last Split Date | Nov 17, 2020 |
| Split Type | Forward |
| Split Ratio | 1054:1000 |
Scores
Pfizer has an Altman Z-Score of 1.62 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.62 |
| Piotroski F-Score | 4 |